ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
Hypoxia-inducible factor (HIF) is an attractive therapeutic target for renal cell carcinoma (RCC) as its high expression due to the loss of von Hippel-Lindau (VHL) promotes RCC progression. Considering this, we hypothesized that ELR510444, a novel orally available small molecule inhibitor of HIF act...
Main Authors: | Jennifer S Carew, Juan A Esquivel, Claudia M Espitia, Christoph M Schultes, Marcel Mülbaier, Joe D Lewis, Bernd Janssen, Francis J Giles, Steffan T Nawrocki |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3266297?pdf=render |
Similar Items
-
Contribution of the ELRs to the development of advanced in vitro models
by: María Puertas-Bartolomé, et al.
Published: (2024-04-01) -
Genome editing abrogates angiogenesis in vivo
by: Huang, Xionggao, et al.
Published: (2017) -
PGF2α facilitates pathological retinal angiogenesis by modulating endothelial FOS‐driven ELR+ CXC chemokine expression
by: Yan Zhao, et al.
Published: (2023-01-01) -
Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma
by: Shariful Islam, et al.
Published: (2021-07-01) -
Autophagy: New Insights into Its Roles in Cancer Progression and Drug Resistance
by: Steffan T. Nawrocki, et al.
Published: (2020-10-01)